Treatment of juxtapapillary hemangioblastoma by intra-arterial (ophthalmic artery) chemotherapy with bevacizumab Journal Article


Authors: Francis, J. H.; Slakter, J. S.; Abramson, D. H.; Odrich, S. A.; Gobin, Y. P.
Article Title: Treatment of juxtapapillary hemangioblastoma by intra-arterial (ophthalmic artery) chemotherapy with bevacizumab
Abstract: Purpose: To report on two cases of treatment-refractory juxtapapillary hemagioblastomas that were managed with intra-arterial bevacizumab delivered via the ophthalmic artery. Observations: Case 1 is a 35 year-old man with juxtapapillary hemangioblastoma who continued to have progressive tractional retinal detachment, optic nerve neovascaularization and cystoid macula edema (CME) despite heavy prior treatment with intravitreal anti-vascular endothelial growth factor (VEGF) and steroid intravitreal injections and laser. Case 2 is a 41 year-old woman with juxtapapillary hemangioblastoma who had progressive tractional retinal detachment, CME and visually-threatening intraocular pressure elevation despite treatment with anti-VEGF injection and laser. Both cases were treated with three infusions of intra-arterial bevacizumab delivered via the ophthalmic artery. Both tumors demonstrated measurable decrease in height, stability of their secondary retinal changes and minimal requirement for additional treatment at 30 mos and 26 mos follow-up, respectively for cases 1 and 2. Conclusions and importance: These cases suggest that higher-dose, targeted delivery of anti-VEGF to hemangioblastomas via ophthalmic artery injection may be useful in stabilizing the disease and abating the typical progression of secondary retinal pathology, at least in the first two years after treatment. © 2018
Keywords: bevacizumab; intra-arterial; retinal angioma; retinal hemangioblastoma; von-hippel landau
Journal Title: American Journal of Ophthalmology Case Reports
Volume: 11
ISSN: 2451-9936
Publisher: Elsevier Inc.  
Date Published: 2018-09-01
Start Page: 49
End Page: 51
Language: English
DOI: 10.1016/j.ajoc.2018.05.007
PROVIDER: scopus
PMCID: PMC6026768
PUBMED: 29978140
DOI/URL:
Notes: Article -- Export Date: 2 July 2018 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Jasmine Helen Francis
    256 Francis
  2. David H Abramson
    389 Abramson